TDG vs ZBIO · P/E 41, rev $8.83B vs rev $10.0M
Transdigm Group Incorporated (TDG) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
TDG currently screens at market cap $73.65B and trailing P/E 41.1. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the TDG and ZBIO stock pages for the full models.
Not investment advice.